Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/folinic acid (FA) in refractory advanced high-grade neuroendocrine cancer (HG-NEC) of gastroenteropancreatic (GEP) or unknown origin.

Medhavi Gupta,Minsig Choi,Robert A. Ramirez,Kristopher Attwood,Sarbajit Mukherjee,Renuka Iyer

Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/folinic acid (FA) in refractory advanced high-grade neuroendocrine cancer (HG-NEC) of gastroenteropancreatic (GEP) or unknown origin.

2020

Medhavi Gupta
Minsig Choi
Robert A. Ramirez
Kristopher Attwood
Sarbajit Mukherjee
Renuka Iyer

TPS636Background: The incidence of GEP HG-NEC is increasing and the prognosis is poor. Etoposide–platinum (EP) combination is considered the standard (std) therapy (Rx), but survival is less than 1...

Keywords:

Irinotecan
Fluorouracil
Phases of clinical research
Internal medicine
Neuroendocrine Cancer
Medicine
Oncology
Folinic acid
Pathology
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations